SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: glass 0.5 full who wrote (4220)4/27/2016 9:39:48 PM
From: jaybe1 Recommendation

Recommended By
tktom

  Read Replies (1) of 4474
 
I think EGFR is used as a comparator since inhibiting EGFR WT is a known limiting toxicity. I'm not counting Her2 out yet but there is room for doubt, or discount, for valuing this cohort. However, this is nothing like Ariad's claim for briga in T790M EGFR. '788's pre-clinical shows cellular IC50's for Her2 Ex. 20 at ~6-26nM, which is at least ~10 times more potent than '113's cellular IC50's for EGFR mutants at 112-694nM (Briga inhibits cellular ALK WT at 17nM for comparison) [Ref. ASCO poster 2013]. So there is likely therapeutic window in Her2, but the higher dose and toxicity could make '788 vulnerable to a better Her2 inhibitor in the future.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News